Meeting
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
Authors
Ian Mitchell McElree
The University of Iowa Carver College of Medicine, Iowa City, IA
Ian Mitchell McElree , Ryan L. Steinberg , Sarah L. Mott , Alexander C. Martin , Jordan Richards , Paul T. Gellhaus , Kenneth G. Nepple , Michael A. O'Donnell , Vignesh T. Packiam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 497)
DOI
10.1200/JCO.2022.40.6_suppl.497
Abstract #
497
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
First Author: Sunil H. Patel
Poster
2023 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guérin for the treatment of high-risk, treatment-naïve, non-muscle invasive bladder cancer.
First Author: Ian M. McElree
Poster
2022 ASCO Genitourinary Cancers Symposium
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.
First Author: Phani T. Chevuru
Poster
2022 ASCO Genitourinary Cancers Symposium
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
First Author: Michiel Simon Van Der Heijden